abusesaffiliationarrow-downarrow-leftarrow-rightarrow-upattack-typeburgerchevron-downchevron-leftchevron-rightchevron-upClock iconclosedeletedevelopment-povertydiscriminationdollardownloademailenvironmentexternal-linkfacebookfiltergenderglobegroupshealthC4067174-3DD9-4B9E-AD64-284FDAAE6338@1xinformation-outlineinformationinstagraminvestment-trade-globalisationissueslabourlanguagesShapeCombined Shapeline, chart, up, arrow, graphLinkedInlocationmap-pinminusnewsorganisationotheroverviewpluspreviewArtboard 185profilerefreshIconnewssearchsecurityPathStock downStock steadyStock uptagticktooltiptwitteruniversalityweb

このページは 日本語 では利用できません。English で表示されています

ストーリー

2014年1月1日

Allegations of pharmaceutical group's planned opposition to So. Africa reforms to increase access to medicines

In January 2014, the Innovative Pharmaceutical Association of South Africa (IPASA) was accused of planning and funding an advocacy campaign on behalf of its member companies. The campaign allegedly sought to oppose South Africa’s efforts to introduce intellectual property law reforms that would allow for patents belonging to IPASA’s member companies to be limited, and for cheaper generic versions to be produced.

In a leaked email, Merck and other members of IPASA discussed the strategy.

Media items on the IPASA campaign:

 

Business & Human Rights Resource Centre invited IPASA and its member companies to respond:

Members companies' responses & non-responses:

  • Abbott [We have invited Abbott to respond and will indicate here whether it responds]
  • Abbvie [We have invited Abbvie to respond and will indicate here whether it responds]
  • Alcon (part of Novartis) Novartis responded [PDF] on behalf of itself and Alcon
  • Allergan did not respond
  • Amgen [We have invited Amgen to respond and will indicate here whether it responds]
  • AstraZeneca response [PDF]
  • Baxter response [PDF]
  • Bayer response [PDF]
  • Boehringer-Ingelheim response [PDF]
  • Bristol-Myers Squibb referred us to IPASA
  • Covidien [We have invited Covidien to respond and will indicate here whether it responds]
  • Eli Lilly [We have invited Eli Lilly to respond and will indicate here whether it responds]
  • Ferring [We have invited Ferring to respond and will indicate here whether it responds]
  • Galderma response [PDF]
  • GE Health reffered us to IPASA
  • Johnson & Johnson response [PDF]
  • Merck (MSD) response [PDF]
  • Novartis response [PDF]
  • Novo Nordisk response [PDF] indicates it resigned from IPASA following campaign proposal:
  • Norgine [We have invited Norgine to respond and will indicate here whether it responds]
  • Pfizer referred us to IPASA
  • Roche response [PDF] indicates it resigned from IPASA following campaign proposal
  • Sanofi-Aventis [We have invited Sanofi-Aventis to respond and will indicate here whether it responds]
  • Servier [We have invited Servier to respond and will indicate here whether it responds]
  • Takeda referred us to IPASA

 

Novo Nordisk and Roche resigned from IPASA:

企業への回答リクエスト

Abbott Laboratories

回答無し

AbbVie

回答無し

Allergan 回答を見る
Amgen

回答無し

AstraZeneca 回答を見る
Baxter International 回答を見る
Boehringer Ingelheim 回答を見る
Bristol-Myers Squibb 回答を見る
Covidien 回答を見る
Eli Lilly 回答を見る
Ferring Pharmaceuticals

回答無し

Galderma 回答を見る
GE Health (part of General Electric) 回答を見る
Johnson & Johnson 回答を見る
Norgine Pharmaceuticals 回答を見る
Novartis 回答を見る
Novo Nordisk (part of Novo Group) 回答を見る
Sanofi

回答無し

Servier

回答無し

Takeda Pharmaceutical 回答を見る

タイムライン

プライバシー情報

このサイトでは、クッキーやその他のウェブストレージ技術を使用しています。お客様は、以下の方法でプライバシーに関する選択肢を設定することができます。変更は直ちに反映されます。

ウェブストレージの使用についての詳細は、当社の データ使用およびクッキーに関するポリシーをご覧ください

Strictly necessary storage

ON
OFF

Necessary storage enables core site functionality. This site cannot function without it, so it can only be disabled by changing settings in your browser.

クッキーのアナリティクス

ON
OFF

When you access our website we use Google Analytics to collect information on your visit. Accepting this cookie will allow us to understand more details about your journey, and improve how we surface information. All analytics information is anonymous and we do not use it to identify you. Google provides a Google Analytics opt-out add on for all popular browsers.

Promotional cookies

ON
OFF

We share news and updates on business and human rights through third party platforms, including social media and search engines. These cookies help us to understand the performance of these promotions.

本サイトにおけるお客様のプライバシーに関する選択

このサイトでは、必要なコア機能を超えてお客様の利便性を高めるために、クッキーやその他のウェブストレージ技術を使用しています。